Ocera Therapeutics: When A Drug Fails, But Actually Works
Seeking Alpha,
Summary OCRX lost 70% of its market cap after near miss in phase 2b trial of OCR-002 in hepatic encephalopathy Subsequent…
Ocera Therapeutics: A Speculative Investment
Seeking Alpha,
In this article, we describe our investment thesis and valuation for Ocera Therapeutics (NASDAQ: OCRX ), an emerging…
Glycerol Phenylbutyrate reduces hepatic encephalopathy events and ammonia levels compared to placebo in a Phase 2 trial
Medical News Today,
Phase 2 trial results published in Hepatology, a journal of the American Association for the Study of Liver Diseases, suggests…
Glycerol Phenylbutyrate Reduces Hepatic Encephalopathy Events
Science Newsline,
Phase 2 trial results published in the March issue of Hepatology, a journal of the American Association for the Study of Liver…